Literature DB >> 8900128

Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity.

S Higashi1, N Matsumoto, S Iwanaga.   

Abstract

The mechanism of the acceleration of the catalytic activity of factor VIIa (VIIa) in the presence of tissue factor (TF) was investigated. To explore the VIIa's site(s) that correlates with TF-mediated acceleration, zymogen VII, VIIa, and active site-modified VIIa were prepared, and dissociation constants (Kd) for their bindings to TF or soluble TF in solution were determined. We found that conversion of zymogen VII to VIIa led to an increase in affinity (DeltaDeltaG = 4.3-4.4 kJ/mol) for TFs. Dansyl-Glu-Gly-Arg chloromethyl ketone (DNS-EGRck) treatment of VIIa led to a further increase in the affinity (DeltaDeltaG = 7.3-12 kJ/mol). Neither removal of the Gla domain from VIIa nor truncation of the COOH-terminal membrane and cytoplasmic regions of TF affected the affinity enhanced after DNS-EGRck treatment of VIIa. Treatment of VIIa with (p-amidinophenyl)methanesulfonyl fluoride also enhanced its affinity for soluble TF, whereas treatment with 4-(2-aminoethyl)benzenesulfonyl fluoride, phenylmethylsulfonyl fluoride, or diisopropyl fluorophosphate had a slight effect on the affinity. On the other hand, DNS-EGRck and (p-amidinophenyl)methanesulfonyl fluoride treatments, but not diisopropyl fluorophosphate treatment, of VIIa led to protection of its alpha-amino group of Ile-153 from carbamylation. Protection of the alpha-amino group was consistent with formation of a critical salt bridge between Ile-153 and Asp-343 in the protease domain of VIIa. Therefore, TF may preferentially bind to the active conformational state of VIIa. When one assumes that free VIIa exists in equilibrium between minor active and dominant zymogen-like inactive conformational states, preferential binding of TF to the active state leads to a shift in equilibrium. We speculate that TF traps the active conformational state of VIIa and converts its zymogen-like state into an active state, thereby accelerating the VIIa activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900128     DOI: 10.1074/jbc.271.43.26569

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Structure of human factor VIIa and its implications for the triggering of blood coagulation.

Authors:  A C Pike; A M Brzozowski; S M Roberts; O H Olsen; E Persson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Antibody-induced enhancement of factor VIIa activity through distinct allosteric pathways.

Authors:  Lisbeth M Andersen; Peter A Andreasen; Ivan Svendsen; Janneke Keemink; Henrik Østergaard; Egon Persson
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

3.  Loop dynamics of the extracellular domain of human tissue factor and activation of factor VIIa.

Authors:  Agnese S Minazzo; Reuben C Darlington; J B Alexander Ross
Journal:  Biophys J       Date:  2009-01       Impact factor: 4.033

4.  Sites involved in intra- and interdomain allostery associated with the activation of factor VIIa pinpointed by hydrogen-deuterium exchange and electron transfer dissociation mass spectrometry.

Authors:  Hongjian Song; Ole H Olsen; Egon Persson; Kasper D Rand
Journal:  J Biol Chem       Date:  2014-10-24       Impact factor: 5.157

Review 5.  The transition of prothrombin to thrombin.

Authors:  S Krishnaswamy
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

6.  Hinge bending within the cytokine receptor superfamily revealed by the 2.4 A crystal structure of the extracellular domain of rabbit tissue factor.

Authors:  Y A Muller; R F Kelley; A M de Vos
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

7.  Binding of Zn2+ to a Ca2+ loop allosterically attenuates the activity of factor VIIa and reduces its affinity for tissue factor.

Authors:  L C Petersen; O H Olsen; L S Nielsen; P O Freskgård; E Persson
Journal:  Protein Sci       Date:  2000-05       Impact factor: 6.725

Review 8.  Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.

Authors:  Muriel Giansily-Blaizot; Jean-François Schved
Journal:  Ther Adv Hematol       Date:  2017-11-03

9.  Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X.

Authors:  L Yang; C Manithody; A R Rezaie
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

Review 10.  Tissue factor: a key molecule in hemostatic and nonhemostatic systems.

Authors:  James H Morrissey
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.